BRPI0417493B8 - uso de uma toxina botulínica para tratamento de distúrbios da pele - Google Patents

uso de uma toxina botulínica para tratamento de distúrbios da pele

Info

Publication number
BRPI0417493B8
BRPI0417493B8 BRPI0417493A BRPI0417493A BRPI0417493B8 BR PI0417493 B8 BRPI0417493 B8 BR PI0417493B8 BR PI0417493 A BRPI0417493 A BR PI0417493A BR PI0417493 A BRPI0417493 A BR PI0417493A BR PI0417493 B8 BRPI0417493 B8 BR PI0417493B8
Authority
BR
Brazil
Prior art keywords
botulinum toxin
skin disorders
treat skin
toxin
disorders
Prior art date
Application number
BRPI0417493A
Other languages
English (en)
Inventor
R First Eric
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0417493A publication Critical patent/BRPI0417493A/pt
Publication of BRPI0417493B1 publication Critical patent/BRPI0417493B1/pt
Publication of BRPI0417493B8 publication Critical patent/BRPI0417493B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

terapia com toxina botulínica para distúrbios da pele. a presente invenção refere-se a métodos para tratamento de distúrbios da pele por administração local de uma toxina clostridial, tal como uma toxina botulínica, a um paciente com um distúrbio de pele, tal como verruga, calosidade ou joanete.
BRPI0417493A 2003-12-09 2004-12-08 uso de uma toxina botulínica para tratamento de distúrbios da pele BRPI0417493B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/731,973 US8048423B2 (en) 2003-12-09 2003-12-09 Botulinum toxin therapy for skin disorders
PCT/US2004/041327 WO2005056050A1 (en) 2003-12-09 2004-12-08 Botulinum toxin therapy for skin disorders

Publications (3)

Publication Number Publication Date
BRPI0417493A BRPI0417493A (pt) 2007-05-29
BRPI0417493B1 BRPI0417493B1 (pt) 2018-11-13
BRPI0417493B8 true BRPI0417493B8 (pt) 2021-05-25

Family

ID=34634457

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417493A BRPI0417493B8 (pt) 2003-12-09 2004-12-08 uso de uma toxina botulínica para tratamento de distúrbios da pele

Country Status (10)

Country Link
US (1) US8048423B2 (pt)
EP (2) EP1691830B1 (pt)
JP (1) JP4937758B2 (pt)
AT (2) ATE446769T1 (pt)
AU (1) AU2004296870B2 (pt)
BR (1) BRPI0417493B8 (pt)
CA (1) CA2549550C (pt)
DE (2) DE602004023886D1 (pt)
ES (2) ES2289591T3 (pt)
WO (1) WO2005056050A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20080008777A1 (en) * 2004-02-12 2008-01-10 Philip Radovic Methods of treating a bunion
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
ATE533853T1 (de) * 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP2298339B1 (en) * 2004-09-23 2015-07-15 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060067950A1 (en) * 2004-09-27 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in wound healing
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
JP6444032B2 (ja) * 2011-01-07 2018-12-26 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療用又は美容用毒素組成物の局所塗布、除去及び不活化のための方法及びキット
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
CN105451710A (zh) 2013-03-22 2016-03-30 利普泰股份公司 用于治疗和/或护理皮肤、粘膜和/或指甲的外泌多糖
JP2020510100A (ja) 2017-03-13 2020-04-02 フィリップ アンドリュー ラドヴィッチ 足の第１中足趾節関節の異常の治療に使用するための神経筋毒素
JP7096845B2 (ja) * 2017-05-31 2022-07-06 アラーガン、インコーポレイテッド メラノサイトの活動亢進および／または過剰メラニンに関連する障害の治療のためのボツリヌス神経毒素

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE69620888T2 (de) * 1996-11-27 2002-08-14 William J Binder Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
ATE314859T1 (de) * 1998-10-27 2006-02-15 Mayo Foundation Botulinumtoxine zur verstärkung der wundheilung
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CA2451923C (en) 2001-07-27 2009-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
EP1534376B1 (en) * 2002-06-25 2016-08-31 Theraject, Inc. Rapidly dissolving micro-perforator for drug delivery and other applications
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Also Published As

Publication number Publication date
ATE369874T1 (de) 2007-09-15
ES2289591T3 (es) 2008-02-01
BRPI0417493A (pt) 2007-05-29
WO2005056050A1 (en) 2005-06-23
JP2007513964A (ja) 2007-05-31
AU2004296870B2 (en) 2010-05-20
DE602004008329D1 (de) 2007-09-27
DE602004008329T2 (de) 2008-05-08
DE602004023886D1 (de) 2009-12-10
CA2549550A1 (en) 2005-06-23
EP1691830B1 (en) 2007-08-15
ATE446769T1 (de) 2009-11-15
EP1820510A1 (en) 2007-08-22
EP1691830A1 (en) 2006-08-23
JP4937758B2 (ja) 2012-05-23
AU2004296870A1 (en) 2005-06-23
US20050123567A1 (en) 2005-06-09
CA2549550C (en) 2012-07-17
US8048423B2 (en) 2011-11-01
ES2335310T3 (es) 2010-03-24
BRPI0417493B1 (pt) 2018-11-13
EP1820510B1 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
NZ603717A (en) Suture line administration technique using botulinum toxins
BR0110030A (pt) Método para tratamento de dor através da administração periférica de uma neurotoxina
BR112013004768A2 (pt) dispositivos e métodos para dilatar uma abertura de seio parasanal e para o tratamento de sinusite
BR0309888A (pt) Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
MXPA03002576A (es) Metodos para tratar lesiones musculares.
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2007100675A3 (en) Collagenase for treating cellulite
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
MX352412B (es) Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
ATE538800T1 (de) Kombinationstherapie zur krebsbehandlung
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
BRPI0919944A2 (pt) aparelho e método para tratamento ultrassônico da espinha
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
MX2019011196A (es) Neurotoxinas botulinas para uso en terapia.
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2463 DE 20/03/2018 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.